Sydney Ugwu - Gurnee IL, US Varda E. Sandweiss - New York NY, US Catherine Hardalo - Morristown NJ, US Roberta S. Hare - Gillette NJ, US Gopal Krishna - North Brunswick NJ, US Zaiqi Wang - Edison NJ, US Marco Taglietti - Watchung NJ, US
International Classification:
A61K 9/14 A61P 31/10
US Classification:
424489
Abstract:
The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics-displayed in FIG.
Particulate-Stabilized Injectable Pharmaceutical Compositions Of Posaconazole
Sydney Ugwu - Gurnee IL, US Varda Sandweiss - New York NY, US Catherine Hardalo - Morristown NJ, US Roberta Hare - Gillette NJ, US Gopal Krishna - North Brunswick NJ, US Zaiqi Wang - Edison NJ, US Marco Taglietti - Watchung NJ, US
International Classification:
A61K 31/496
US Classification:
514254070
Abstract:
The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics, such as those displayed below.
Resumes
Member Of The Orchestra Of St Luke Board Of Directors
Orchestra of St. Luke's
Member of the Orchestra of St Luke Board of Directors
Nephrogenex Sep 1, 2014 - Sep 2017
Member of the Board of Directors
Bionj Sep 1, 2014 - Sep 2017
Director, Bionj Board of Trustees
Scynexis, Inc. Sep 1, 2014 - Sep 2017
President and Chief Executive Officer
Scynexis, Inc. Sep 1, 2014 - Sep 2017
Member of the Board of Directors
hase III trials in schizophrenia and bipolar mania, we now have positive Phase IIb studies for cariprazine in both bipolar depression and major depressive disorder. Our goal is to continue developing cariprazine for patients with a broad range of psychiatric conditions, said Marco Taglietti, M.D.,
Date: Mar 31, 2014
Category: Health
Source: Google
Richter, Forest Announce Positive IIb Results for Cariprazine for Bipolar ...
completed Phase III trials in schizophrenia and bipolar mania, we now have positive Phase IIb studies for Cariprazine in both bipolar depression and major depressive disorder. Our goal is to continue developing Cariprazine for patients with a broad range of psychiatric conditions," said Marco Taglietti, M.
Date: Mar 31, 2014
Category: Health
Source: Google
Forest, Richter Schizophrenia Drug Met Clinical Trial Goals
By successfully meeting the primary endpoint in each of these studies, we now have three positive schizophrenia trials and three positive bipolar mania trials, said Marco Taglietti, the senior vice president for research and development at New York-based Forest.
"Today shows our commitment to the COPD community with a second product to treat a very common disease," said Dr. Marco Taglietti, senior vice president for research and development at Forest Laboratories.